BOEHRINGER-INGELHEIM
5.10.2022 09:11:35 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that Cowtribe is the first recipient of investment and non-financial support from the Boehringer Ingelheim Social Engagement (BI SE) initiative, a program which aims to close a critical financing gap for social businesses in vulnerable communities.
Cowtribe, a leading last-mile veterinary delivery company from Ghana, leverages technology to help coordinate deliveries of veterinary vaccines and other animal health products to rural and underserved communities, where many farmers are dependent on just a few animals.
With innovative solutions, such as software supported demand & supply matching, as well as a partnership for drone delivery, Cowtribe bridges the final, critical last mile to get animal medication and veterinary vaccines to smallholder farmers in remote areas. The social start-up, which was founded in 2017, plans to expand to other African markets and collaborates with the government of Ghana on a national livestock identification system, based on Cowtribe’s market data and network.
Start-ups often need more than just funding. BI SE was launched in 2021 to provide investment and non-financial support, together with complementary partners and by engaging Boehringer Ingelheim’s employees to help scale up solutions of social businesses to create systemic change.
BI SE underlines Boehringer Ingelheim’s commitment to find innovative financing solutions with the intention to scale social impact. It complements Boehringer Ingelheim’s flagship initiative, Making More Health, which has committed to positively impact the lives and health of 50 million people through supporting social entrepreneurs in vulnerable communities.
“We are delighted to grant the first investment of Boehringer Ingelheim Social Engagements to Cowtribe,” said Ilka Wicke, Global Head of Making More Health at Boehringer Ingelheim. “Every year smallholder farmers lose about 25 percent of their livestock, due to preventable diseases. Cowtribe is at the forefront of addressing this problem by transforming the critical last-mile distribution in Africa. Their smart logistics platform, based on demand optimization, combined with innovative drone delivery concepts, helps secure the availability and accessibility of vaccines for smallholder farmers. Together, we can significantly improve the lives of many farmers across Africa.”
“In Africa, there are over 200 million smallholder farmers without access to reliable animal health services. We are incredibly excited to partner with BI SE to support our mission to make access to animal vaccines in Africa a right, not a privilege,” added Peter Awin, co-founder and CEO of Cowtribe. “This funding will be used to accelerate our growth in Ghana. This will involve entering new communities and building robust tech capabilities, product development, and attracting new talent.”
Financial details will not be disclosed. The news was announced during the “Making More Health Together 2022" convention, a two-day hybrid event, which focuses on the empowerment of social entrepreneurship and topics relevant to human and animal health, as well as social innovation.
Click here for the full release: https://www.boehringer-ingelheim.com/investment-social-engagements-cowtribe-veterinary-startup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005338/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
